The Medicines Patent Pool has announced the expansion of its mandate to cover hepatitis C and tuberculosis treatment. The MPP was previously concentrating only on HIV medicines. The Medicines Patent Pool works to lower drug prices through voluntary licensing and patent pooling. According to the MPP press release, the UNITAID (which created the MPP in 2010) Executive Board meeting approved the MPP's "proposal to improve access to both life-saving direct acting antivirals (DAAs) to treat hepatitis C and new and re-purposed medicines for tuberculosis." Building on its current HIV model, the MPP said it will seek to licence new hepatitis C medicines for generic manufacture. New generations of hepatitis medicines are extremely costly, placing them out of reach of poor populations and is even creating issues for government procurement in developed countries. To date, according to the press release, the MPP has signed agreements for...
Medicines Patent Pool Expands To Include Hepatitis C, Tuberculosis
|Author:||Gusmao & Labrunie|
|Profession:||Gusmao & Labrunie|
To continue readingREQUEST YOUR TRIAL